Wells Fargo & Company Exscientia PLC Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Exscientia PLC stock. As of the latest transaction made, Wells Fargo & Company holds 407,345 shares of EXAI stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

407,345

Previous 492,111 17.22%

Holding current value

$1.97 Million

Previous $2.51 Million 20.81%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$4.26 - $6.0 $361,103 - $508,596	-84,766 Reduced 17.22%	407,345 $1.99 Million
Q2 2024 Aug 13, 2024	SELL	$3.99 - $6.04 $279,260 - $422,739	-69,990 Reduced 12.45%	492,111 $2.51 Million
Q1 2024 May 10, 2024	BUY	$5.3 - $7.51 $2.37 Million - $3.36 Million	446,831 Added 387.64%	562,101 $3.22 Million
Q4 2023 Feb 09, 2024	SELL	$4.35 - $6.88 $389,394 - $615,870	-89,516 Reduced 43.71%	115,270 $738,000
Q3 2023 Nov 13, 2023	SELL	$4.52 - $8.9 $242,461 - $477,413	-53,642 Reduced 20.76%	204,786 $925,000
Q2 2023 Aug 15, 2023	SELL	$4.79 - $8.3 $125,919 - $218,190	-26,288 Reduced 9.23%	258,428 $1.53 Million
Q1 2023 May 12, 2023	BUY	$5.3 - $10.93 $1.51 Million - $3.11 Million	284,116 Added 47352.67%	284,716 $1.51 Million
Q4 2022 Feb 13, 2023	SELL	$4.1 - $8.94 $1,402 - $3,057	-342 Reduced 36.31%	600 $3,000
Q3 2022 Nov 14, 2022	SELL	$7.27 - $12.92 $643,460 - $1.14 Million	-88,509 Reduced 98.95%	942 $8,000
Q2 2022 Aug 12, 2022	SELL	$6.92 - $15.97 $219,114 - $505,674	-31,664 Reduced 26.14%	89,451 $974,000
Q1 2022 May 16, 2022	BUY	$11.52 - $22.05 $1.4 Million - $2.67 Million	121,115 New	121,115 $1.74 Million

Others Institutions Holding EXAI

# of Institutions

101

Shares Held

33.5M

Call Options Held

500

Put Options Held

189K

View Full List

About Exscientia plc

Ticker EXAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,461,000
Market Cap $593M
Description
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on s...

More about EXAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Exscientia PLC Transaction History